Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. Issue 104 (July 2018)

• Record Type: Journal Article
• Authors: Bali, Maria Antonietta; Pullini, Serena; Metens, Thierry; Absil, Julie; Chao, Shih-Li; Marechal, Raphael; Matos, Celso; Peerboccus, Bibi Mooneera; Van Laethem, Jean-Luc
• Is Part Of: European journal of radiology. Issue 104(2018)
• Page Start: 49
• Page End: 57
• Publication Date: 2018-07
• Subjects: ADC apparent diffusion coefficient -- CBR clinical benefit response -- CT computed tomography -- D pure diffusion -- DW diffusion weighted -- H-ADC histogram-apparent diffusion coefficient -- H-D histogram-pure diffusion -- H-PF histogram-perfusion fraction -- MR magnetic resonance -- PDA pancreatic ductal adenocarcinoma -- PF perfusion fraction -- RECIST response evaluation criteria for solid tumour -- ROI region of interest -- SD stable disease -- STIR short T1 inversion recovery; Pancreatic ductal adenocarcinoma -- Magnetic resonance -- Diffusion-weighted MR imaging -- Oncology -- Treatment response; Medical radiology -- Periodicals; Radiology -- Periodicals; Radiologie médicale -- Périodiques; Medical radiology; Periodicals; 616.075705
• DOI: 10.1016/j.ejrad.2018.04.024
• Languages: English
• ISSNs: 0720-048X

Abstract

Highlights: In PDA DW-MR treatment response assessment is more accurate than RECIST. 25th percentile H-D may predict early response to chemotherapy in PDA. DW-volume accurately categorizes PDA patients in responding and non-responding. Accurate categorization of PDA patients may avoid treatment-related secondary effects. Abstract: Purpose: To prospectively assess chemotherapy-induced changes in pancreatic ductal adenocarcinoma (PDA) with diffusion-weighted (DW)-MR quantitative metrics, including apparent diffusion coefficient (ADC) and histogram-derived parameters, compared with RECIST 1.1. Methods: 24 patients underwent DW-MR at baseline, week-2 and week-8 after chemotherapy initiation. Tumour diameter was assessed on T2-weighted images. Regions-of-interest (ROI) were drawn on ADC map for ROI-ADC. Volume segmentation (b = 1000 s/mm 2 images) provided DW-volume and histogram-derived diffusion parameters (H-ADC, H-D and H-PF). All variables and their relative change were compared to baseline or between responders and non-responders. Discriminant analysis was performed. Results: 15/24 patients were responders. RECIST 1.1 correctly characterized 6/15 responders at week-8. At week-2, in responders DW-volume decreased (P = .002); ROI-ADC mean H-D increased (P = .047; P = .048;). The 25th percentile H-D increased in responders and decreased in non-responders (P = .016; P = .048). At week-8 in responders DW-volume decreased and ROI-ADC mean, 25th, 50th, 75th percentiles of H-ADC and H-D increased (P < .05). No changes were observed in non-responders (P > .05). At week-2, 25th percentile of H-D and H-PF relative change correctly classified 20/24 patients (P = .003); at week-8, DW-volume relative change correctly classified 22/24 patients (P < .0001). Conclusions: ROI-ADC, DW-volume and histogram-derived diffusion parameters are more accurate to categorize responding and non-responding PDA patients treated with chemotherapy compared with RECIST 1.1.